**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 28894**

**Manuscript Type:****ORIGINAL ARTICLE**

***Basic Study***

**Effects of *Saccharomyces cerevisiae* or *boulardii* yeasts on acute stress induced intestinal dysmotility**

WestC *et al. Saccharomyces* relieve stressed gut dysmotility

Christine West, Andrew M Stanisz, Annette Wong, Wolfgang A Kunze

**Christine West, Andrew M Stanisz, Annette Wong, Wolfgang A Kunze,** McMaster Brain-Body Institute, St. Joseph’s Healthcare, Hamilton, ON L8N 4A6, Canada

Wolfgang A Kunze, Department of Biology, McMaster University, Hamilton, ON L8S 4L8, Canada

Wolfgang A Kunze, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON L8S 4L8, Canada

Author contributions: West C, Wong A, and Stanisz AM acquired and analyzed the data; Stanisz AM performed pilot experiments; West C and Kunze WA drafted the manuscript; Kunze WA designed the research.

Supported by the Natural Sciences and Engineering Research Council of Canada Discovery Grant awarded (to Kunze W), No. 2014-05517.

Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Animal Research Ethics Board of McMaster University (AUP# 12-05-17).

Conflict-of-interest statement: There are no conflicts of interest.

Data sharing statement: No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

Correspondence to: Christine West, MSc Candidate, BSc, McMaster Brain-Body Institute, St. Joseph’s Healthcare, Hamilton, 50 Charlton Street East, ON L8N 4A6, Canada. westcl2@mcmaster.ca

Telephone: +1-905-5221155

Fax: +1-905-5406593

**Received:** July 20, 2016

**Peer-review started:** July 21, 2016

**First decision:** August 22, 2016

**Revised:** September 15, 2016

**Accepted:** October 10, 2016

**Article in press:**

**Published online:**

 Abstract

***AIM***

To investigate the capacity of *Saccharomyces cerevisiae* (*S. cerevisiae*) and *Saccharomyces* *boulardii* (*S. boulardii*) yeasts to reverse or to treat acute stress-related intestinal dysmotility.

***METHODS***

Adult Swiss Webster mice were stressed for 1 h in a wire-mesh restraint to induce symptoms of intestinal dysmotility and were subsequently killed by cervical dislocation. Jejunal and colon tissue were excised and placed within a tissue perfusion bath in which *S. cerevisiae*, *S. boulardii,* or their supernatants were administered into the lumen. Video recordings of contractility and gut diameter changes were converted to spatiotemporal maps and the velocity, frequency, and amplitude of propagating contractile clusters were measured. Motility pre- and post-treatment was compared between stressed animals and unstressed controls.

***RESULTS***

*S. boulardii* and *S.* *cerevisiae* helped to mediate the effects of stress on the small and large intestine. Restraint stress reduced jejunal transit velocity (mm/s) from 2.635 ± 0.316 to 1.644 ± 0.238, *P <* 0.001 and jejunal transit frequency (Hz) from 0.032 ± 0.008 to 0.016 ± 0.005, *P <* 0.001. Restraint stress increased colonic transit velocity (mm/s) from 0.864 ± 0.183 to 1.432 ± 0.329, *P <* 0.001 and frequency to a lesser degree. Luminal application of *S.* *boulardii* helped to restore jejunal and colonic velocity towards the unstressed controls; 1.833 ± 0.688 to 2.627 ± 0.664, *P <* 0.001 and 1.516 ± 0.263 to 1.036 ± 0.21, *P <* 0.001, respectively. *S. cerevisiae* also had therapeutic effects on the stressed gut, but was most apparent in the jejunum. *S. cerevisiae* increased PCC velocity in the stressed jejunum from 1.763 ± 0.397 to 2.017 ± 0.48, *P =* 0.0031 and PCC frequency from 0.016 ± 0.009 to 0.027 ± 0.007, *P <* 0.001. *S. cerevisiae* decreased colon PCC velocity from 1.647 ± 0.187 to 1.038 ± 0.222, *P <* 0.001. Addition of *S. boulardii* or *S. cerevisiae* supernatants also helped to restore motility to unstressed values in similar capacity.

***CONCLUSION***

There is a potential therapeutic role for *S. cerevisiae* and *S.* *boulardii* yeasts and their supernatants in the treatment of acute stress-related gut dysmotility.

**Key words:** Intestine; *Saccharomyces* *cerevisiae*; *Saccharomyces* *boulardii*; Restraint stress; Motility

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The use of *Saccharomyces cerevisiae* and *Saccharomyces* *boulardii* yeasts as therapeutic agents were tested for their ability to reverse the intestinal discomfort caused by acute stress. Most studies investigate the role of microbes in the prevention of stress, however the yeasts showed promising acute therapeutic effects for the treatment of stress. Additionally, the residual supernatant after centrifugation of the yeasts was able to recapitulate much of the effect of the microbes themselves. *Saccharomyces* yeasts or supernatant may be potential probiotic therapies in the treatment of acute stress-related intestinal dysmotility.

West C, Stanisz AW, Wong A, Kunze WA. Effects of *Saccharomyces cerevisiae* or *boulardii* yeasts on acute stress induced intestinal dysmotility. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Most studies on beneficial ingested microbes (BIMs) including probiotics have focused primarily on bacteria. However, beneficial roles have been ascribed to certain yeasts, such as the sugar-fermenting *Saccharomyces*[1]. *Saccharomyces* *boulardii* (*S. boulardii*) and *Saccharomyces cerevisiae* (*S. cerevisiae*)are two closely related strains used either as a probiotic or in the preparation of food and wine. The two strains have been closely examined; revealing that although they are nearly identical at a molecular level, *S. boulardii* shows more physiological resistance to heat and acid stressors[2]. It should also be noted that *S. boulardii* does not produce acospores or use galactose, while *S. cerevisiae* does[3,4].

*S. boulardii* has been systematically studied for its beneficial and probiotic effects[5], but *S. cerevisiae* has limited research supporting a probiotic role[1]. *S. boulardii* has been used to help in the prevention of antibiotic or *Clostridium difficile* induced diarrhea, and there is evidence that it may be useful in attenuating acute gastroenteritis and traveller's diarrhea[5,6]. Another study showed that treatment with *S. boulardii* helped to shorten the duration of acute diarrhea in children and to normalize the frequency and consistency of stool[7]. *S. boulardii* may also help in the treatment of bowel inflammation and infection by reversing mucosal injury[8].

*S. cerevisiae* food and wine strains have a long history in the food and wine industry[9] and are generally considered safe for consumption[1]. Suggestive for a potential beneficial role for *S. cerevisiae* are reports indicating that this strain may provoke immune stimulation in mice infected with *Staphylococcus aureus*[10]. Supplementation with a *S. cerevisiae* I-3856 strain may improve symptoms in constipation-predominant irritable bowel syndrome patients[11]. There is also evidence that a *S. cerevisiae* UFMG 905 strain can bind to bacteria and modulate inflammation pathways in a murine model of *Salmonella enterica serovar Typhimurium* infection[12]. In summary, there appears to be published data supporting roles for *S. boulardii* or *S. cerevisiae* as beneficial or probiotic microbes. The evidence seems to be stronger for *S. boulardii* than *S. cerevisiae*, perhaps because the latter has been less frequently investigated in this regard.

We used an acute *ex vivo*, before and after, motility recording paradigm similar to that used previously to test for the effects of JB-1™ on stress-induced dysmotility[13]. *Saccharomyces* or *Saccharomyces* supernatant were added to the Krebs buffer perfusing the lumen of isolated, previously stressed or unstressed, mouse intestinal segments. Treatment effects were interpreted by comparing propagating contractile clusters (PCC) of control with treatment recording periods. The *ex vivo* design allowed us to localize any effects to the intestine, thus avoiding multisystem homeostatic feedback between the gut and its extrinsic nervous system. This design also allowed us to separate treatment effects from confounding preventative actions, as would have been the case if the yeasts had been fed to the animal.

The preventative effect of *Saccharomyces* strains in relation to diarrhea suggests a possible action on disordered gut motility. It has not been experimentally tested whether *S. boulardii* or *S. cerevisiae* are able to treat (effectively reverse) stress-related dysmotility in an experimental model. We have recently shown that restraint stress induces colonic propulsive hypermotility, while disorganizing and reducing motility in the small intestine[13]. The effects of stress on motility could be reversed *ex vivo* by introducing a bacterial probiotic (*Lactobacillus rhamnosus* JB-1™) into the lumen[13]. The example of JB-1™ in treating stress-induced dysmotility provides a way to compare putative beneficial actions of the *Saccharomyces* strains with a probiotic bacterium whose effects on motility and the enteric nervous system have been previously studied[14-20].

**MATERIALS AND METHODS**

***Animals***

We used 6-8 wk old adult male Swiss Webster mice (20–30 g) from Charles River Laboratories (Wilmington, MA, USA). All procedures following acute restraint were *ex vivo*[20] and their conduct were approved by the Animal Research Ethics Board of McMaster University (AUP 12-05-17).

***Gut motility***

The following experiments and data analysis were performed as described as in West *et al*[13,20]. Mice were placed in a wire mesh restraint device for 1 h or kept in their cage for 1 h; after which they were killed by cervical dislocation. A 4 cm long segment of jejunum or colon was excised and placed into a tissue bath perfusion chamber[20]. The oral and anal ends were cannulated with silicone tubing and the oral end was attached to a stopcock manifold, allowing inflow with oxygenated Krebs buffer or buffer to which yeast or supernatant (Snt) had been added. Krebs buffer was of the following composition (mmol l-1): 118 NaCl, 4.8 KCl, 25 NaHCO3, 1.0 NaH2PO4, 1.2 MgSO4, 11.1 glucose, and 2.5 CaCl2 bubbled with carbogen gas (95% O2 and 5% CO2). PCCs were evoked by filling the lumen with Krebs buffer using a pressure differential of 2 hPa (cm H2O) for the inflow and 3 hPa for outflow for jejunum, and 2-3 hPa for colon inflow with the outflow raised 1 cm above the inflow.

Contractions of the gut were video-recorded on a JVC camcorder placed 10 cm above the tissue bath. Conversion of videos to spatiotemporal diameter maps (Dmaps) were performed using Image J software, as described in Wu *et al*[20]. Dmaps are a form of heat map in which the oral to anal propagation of the intestine runs down the vertical axis and time runs across the horizontal axis. The intestine’s diameter is colour coded using red to represent contraction, and yellow to green to represent varying degrees of relaxation (Figure 1). PCCs are identified in Dmaps as described in West *et al*[13]. The PCCs appear as broad bands[20] that propagate in the oral to anal direction. They are believed to require ENS activity because they are abolished by the Na channel blocker tetrodotoxin[18-23]. From these Dmaps, velocity can be measured as the slope of the bands (distance/time), frequency from the intervals between the bands, and amplitude as the difference between gut diameters.

***Luminal stimuli***

Lyophilized *S. boulardii* CNCM I-1079 or *S. cerevisiae* LYCC 6029 were obtained from Lallemand Health Solutions (Montreal, QC, CA). The microbes (starter counts) were diluted in 50 mL Krebs buffer and incubated for 45 min at 37 °C. In pilot experiments, 5 × 107, 5 × 108 and 5 × 109 starter counts of *S. boulardii* reduced PCC velocity in unstressed colon segments by 5%, 25% and 27%. We thus used 5 × 108-lyophilized microbes for dilution in all other experiments as this starter count produced near maximal effect in the pilots. In some experiments we used *S.* *boulardii* or *S.* *cerevisiae* supernatant (Snt) after completion of the incubation period. The microbes were diluted and incubated as previously described above. The Snt was separated from the post-incubation yeast microbe solution by centrifugation at 1400 g. using a Beckman Model TJ-6 centrifuge for 30 min. After sediment removal, the mixture was passed through a 0.2 µm pore-size filter and the filtered supernatant was applied to the lumen of gut segment to be tested.

***Statistical analysis***

Effects of restraint stress on motility were measured in unpaired experiments by comparing velocity, frequency and peak amplitude for PCCs. The same parameters were compared before and after application of *S. boulardii*, *S. cerevisiae*, or their supernatant. Control recordings were made in stressed or unstressed mice perfused with Krebs for a maximum of 20 min. Treatment recordings were made during and after addition of one of the stimuli (yeast or supernatant) to the same segment for additional 20 min duration. Descriptive statistics were given as mean ± SD (N, where N denotes the number of mice used). In the results, treatment effect sizes are presented as % mean differences and the probability of superiority (PS) based on distribution of difference scores and standard deviations is presented in brackets [24]. Differences were also presented in the tables using unpaired or paired t tests under the null hypothesis of no difference.

**RESULTS**

***Effects of stress on PCCs***

Stress had different effects on the jejunum versus the colon. Stress decreased propulsive motility and decreased the regularity of PCCs in jejunum, but increased motility in colon (Figure 1). Stress decreased jejunal PCC velocity by 38% (PS = 99%; *P <* 0.001), but increased it by 66% (PS = 98%; *P <* 0.001) for colon (Table 1, Figure 1). Frequency decreased by 50% (PS = 99%; *P <* 0.001) for jejunum, but increased by 27% (PS = 93%; *P =* 0.008) for colon. Peak amplitude increased by 81% (PS = 99%; *P <* 0.001) for jejunum and by 1% (PS = 51%; *P =* 0.902) for colon.

***S. boulardii* unstressed gut**

*S. boulardii* increased PCC velocity in unstressed jejunum by 26% (PS = 94%; *P <* 0.001), but decreased velocity by 27% (PS = 89%; *P <* 0.001) for colon. Frequency was increased by 19% (PS = 74%; *P =* 0.030) for jejunum, but decreased by 22% (PS = 85%; *P =* 0.005) for colon. Peak amplitude increased by 6% (PS = 60%; *P =* 0.290) for jejunum, but decreased by 13% (PS = 85%; *P =* 0.005) for colon (Table 2). Figure 2 also shows paired mean differences (Unstressed + *S. boulardii* Unstressed) with 95%CIs. When the confidence intervals did not straddle the "difference = 0" line, the value of no paired difference was excluded for these intervals with 95% confidence[25]; when it did straddle the "difference = 0" line the value of no paired difference was included within the intervals with 95% confidence.

***S. boulardii* *stressed gut***

*S. boulardii* counter the effects of stress in both jejunal and colon segments, with the exception of peak amplitude (Figure 3, Table 3). *S. boulardii* restored the regularity and frequency of contractions in both tissues, as shown in Figure 3. There is a marked increase in frequency of bands in the jejunal Dmap and a decrease in the colon Dmap. Addition of *S. boulardii* increased velocity by 43% (PS = 93%; *P <* 0.001) for stressed jejunum and decreased velocity by 32% (PS = 96%; *P <* 0.001) for colon. PCC frequency was increased by 69% (PS = 85%; *P =* 0.005) for jejunum but decreased by 29% (PS = 90%; *P =* 0.001) for colon. Peak amplitude changed by +1% (PS = 56%; *P =* 0.705) for jejunum and decreased by 9% (PS = 68%; *P =* 0.259) for colon. Mean paired differences (Stressed +*S. boulardii* Stressed) are given in Figure 3 B,D with their 95%CIs. Washout with Krebs buffer for 20 min during the control period did not moderate the effects of *S. boulardii* on the stressed segments.

***S. cerevisiae* unstressed gut**

*S. cerevisiae* had the most noticeable effect on the jejunum (Figure 4, Table 4). Velocity increased 9% (PS = 71%; *P =* 0.017) for jejunum and 9% (PS = 73%; *P =* 0.161) for colon. Frequency increased by 13% (PS = 64%; *P =* 0.003) for jejunum and by 6% (PS = 63%; *P =* 0.462) for colon, while peak amplitude increased by 7% (PS = 61%; *P =* 0.242) for jejunum, but decreased by 9% (PS = 73%; *P =* 0.164) for colon.

***S. cerevisiae* stressed gut**

*S. cerevisiae* reduced most of the effects of stress, except for those of colon PCC frequency and amplitude (Figure 5, Table 5). Velocity was increased by 14% (PS = 89%; *P =* 0.0031) for jejunum and decreased by 37% (PS = 98%; *P <* 0.001) for colon. Frequency was increased by 74% (PS = 95%; *P <* 0.001) for jejunum, but there was only a 0.1% (PS = 50%; *P =* 0.994) change for colon. Peak amplitude decreased by 27% (PS = 86%; *P =* 0.013) for jejunum and 7% (PS = 72%; *P =* 0.190) for colon. The Dmaps in Figure 5B and D show the regulation of jejunal motility by *S. cerevisiae*, with less potent effects on the colon. However the degree in which the contractions change in diameter appear to be lessened in the colon after addition of *S. cerevisiae*, and is apparent by the reduced frequency of red, strong contractions.

***S. boulardii* Snt stressed gut**

*S. boulardii* supernatant (Snt) decreased the effects of stress on PCC parameters, except for peak amplitude (Figure 6, Table 6). Velocity increased by 31% (PS = 99.9%; *P <* 0.001) for jejunum, but decreased by 30% (PS = 99.9%; *P =* 0.038) for colon. Frequency increased by 114% (PS = 99.9%; *P =* 0.067) for jejunum and decreased by 37% (PS = 99%; *P =* 0.024) for colon. However, peak amplitude only decreased by 2% (PS = 56%; *P =* 0.930) for jejunum and increased 8% (PS = 74%; *P =* 0.590) for colon.

***S. cerevisiae* Snt stressed gut**

*S. cerevisiae* supernatant (Snt) reduced the effects of stress for colon velocity, jejunal frequency and peak amplitude for jejunum and colon (Figure 7, Table 7). Effects on other parameters were minor. Velocity decreased by 7% (PS = 56%; *P =* 0.970) for jejunum but increased by 38% (PS = 99%; *P =* 0.002) for colon. Frequency increased by 64% (PS = 83%; *P =* 0.003) for jejunum and decreased by 2% (PS = 60%; *P =* 0.830); also, peak amplitude decreased by 35% (PS = 99%; *P =* 0.0016) for jejunum while it decreased by 31% (PS = 99%; *P =* 0.100) for colon.

**DISCUSSION**

We have used an *ex vivo* intestinal segment perfusion setup to show that *S. boulardii* or *S.* *cerevisiae* reverse much of the jejunal or colonic dysmotility induced by restraint stress. There is sometimes a potential for normal commensal, or otherwise beneficial, yeasts to adopt a pathological role in immune-compromised individuals. It is therefore of interest that the supernatant from either *Saccharomyces* strains recapitulate much of the treatment effects of the live yeasts. Because the yeasts were applied intraluminally in *ex vivo* intestinal segments the treatment effect must have occurred locally within the intestine[13]. Therefore, it could not have involved the hypothalamic-pituitary-adrenal axis or other central structures. The relative short latency (~10 min) for the onset of the therapeutic effect is consistent with a drug-like pharmacological mode of action, however, fast indirect modes of action involving immune cells cannot be excluded, although we consider the latter possibility to be less likely than the former.

There have been previous reports of the acute *ex vivo* actions of bacterial, but not fungal microbes on intestinal motility (see discussion in[20]). Such effects appear to be region specific with different actions for small versus large intestine[20]. It is important to note that others have also reported a short (~10 min) latency in onset for microbial effects on intestinal propulsive motility[18,26], consistent with a drug-like pharmacological action of the microbes on the neuromuscular machinery. This supporting finding as well as the region-specific, local effect on the intestine leads us to believe the effect is most likely pharmacological in action.

Wrap restraint has been reported to increase the contractile amplitudes in the small intestine and colon, while decreasing frequency in small intestine and increasing frequency in colon[13,27]. As far as we are aware the only other publication to date referring to treatment effects of beneficial microbes on stress-induced dysmotility is West *et al*[13] in which *Lactobacillus rhamnosus* JB-1™ reversed the effects of prior stress. *S. boulardii* or *S. cerevisiae* were also effective in reversing most, but not all of the stress-induced dysmotility. *S. boulardii* was particularly effective in reversing the effects of stress in both the jejunum and colon. *S. boulardii* also had similar effects in the unstressed gut as the stressed, increasing PCC frequency and velocity in the jejunum and decreasing PCC frequency and velocity in the colon. These effects on the unstressed gut were predictive of the restoration of the stressed gut towards unstressed measures.

*S. boulardii* and *S. cerevisiae* are nearly identical genetically, but differ in resistance to temperature and acidic stressors and growth characteristics[2]. Similarly, the treatment effects of *S. boulardii* and *S. cerevisiae* were not identical, indicating that despite their genetic similarity the functional interaction of these microbes or their supernatant with the host intestine is functionally different and region specific. There is clearly a need to identify the bioactive molecules released by the yeasts and those that mediate the motility modifying effects on the host tissue. This is likely a difficult task since there is no reason to suppose that only a single molecule is the mediator for anyone strain; yeasts like other microbes produce a multitude of molecules, of which any combination could potentially be effective. A similar logic applies to bacterial microbes with motility modifying effects. Previous research on *Lactobacillus rhamnosus* JB-1™ isolated the molecule-containing microvesicles of the bacteria and tested them for their individual effect. Application of the microvesicles to the gut epithelium replicated the effects of the JB-1™ bacteria on enteric neurons [28]. In similar fashion, further isolating components of the supernatant and evaluating their effects may help to narrow down the underlying bioactive molecules.

The results of the present paper suggest that there may be other yeasts with potential therapeutic actions in animal models of stress. Our *ex vivo* perfusion setup may provide a relatively simple, though not high throughput, method to screen yeasts or fungi for beneficial effects on the host intestine. Previously discussed results of *S. cerevisiae* and *S. boulard*ii clinical trials further support the therapeutic potential of *Saccharomyces* yeasts in humans[7,11]. We predict that the beneficial or probiotic potential of fungi and yeasts is set to expand with increased research, initially in animal models followed by human trials.

**COMMENTS**

***Background***

Stress has adverse effects on intestinal motility causing irregular PCCs that decrease motility in the jejunum and increase motility in the colon. *Saccharomyces* yeasts have been shown to have potential beneficial and probiotic effects in the intestine and in the treatment of some gastrointestinal disorders.

***Research frontiers***

Most stress and probiotic research studies focus on the prevention of stress-related symptoms on the intestinal tract. The use of probiotics, including yeasts, is an emerging treatment option for gastrointestinal disorders, particularly in exchange for antibiotics.

***Innovations and breakthroughs***

This is first evidence of *Saccharomyces* yeasts acting in the pre-clinical treatment of stress-related gut dysmotility. It is also the first evidence of *Saccharomyces* supernatant (yeast microbes removed) having a beneficial effect on gut motility and the treatment of stress.

***Applications***

The data suggests that *Saccharomyces* yeasts may be potential therapeutic treatments for stress-related dysmotility in the intestine. Additionally, *Saccharomyces* supernatants cause similar effects as their respective yeasts, and might also play a therapeutic role. However, more animal experiments are needed to better support these results.

***Terminology***

PCCs or propagating contractile clusters are sweeping bands of intestinal contraction that move in the oral to anal direction and are likely stimulated by the ENS.

***Peer-review***

The authors investigated the possible effects of *Saccharomyces boulardii* or *Saccharomyces cerevisiae* on reducing the stress-related intestinal dysmotility. The study is well designed and well implemented. The manuscript should be accepted for publication with the following revision.

**REFERENCES**

1 **Moslehi-Jenabian S**, Pedersen LL, Jespersen L. Beneficial effects of probiotic and food borne yeasts on human health. *Nutrients* 2010; **2**: 449-473 [PMID: 22254033 DOI: 10.3390/nu2040449]

2 **Fietto JL**, Araújo RS, Valadão FN, Fietto LG, Brandão RL, Neves MJ, Gomes FC, Nicoli JR, Castro IM. Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. *Can J Microbiol* 2004; **50**: 615-621 [PMID: 15467787 DOI: 10.1139/w04-050]

3 **Edwards-Ingram L**, Gitsham P, Burton N, Warhurst G, Clarke I, Hoyle D, Oliver SG, Stateva L. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. *Appl Environ Microbiol* 2007; **73**: 2458-2467 [PMID: 17293506 DOI: 10.1128/AEM.02201-06]

4 **McFarland LV**. Saccharomyces boulardii is not Saccharomyces cerevisiae. *Clin Infect Dis* 1996; **22**: 200-201 [PMID: 8825013 DOI: 10.1093/clinids/22.1.200]

5 **Czerucka D**, Piche T, Rampal P. Review article: yeast as probiotics -- Saccharomyces boulardii. *Aliment Pharmacol Ther* 2007; **26**: 767-778 [PMID: 17767461 DOI: 10.1111/j.1365-2036.2007.03442.x]

6 **Barnes D**, Yeh AM. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. *Nutr Clin Pract* 2015; **30**: 747-759 [PMID: 26538058 DOI: 10.1177/0884533615610081]

7 **Htwe K**, Yee KS, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. *Am J Trop Med Hyg* 2008; **78**: 214-216 [PMID: 18256417]

8 **Canonici A**, Siret C, Pellegrino E, Pontier-Bres R, Pouyet L, Montero MP, Colin C, Czerucka D, Rigot V, André F. Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor. *PLoS One* 2011; **6**: e18427 [PMID: 21483797 DOI: 10.1371/journal.pone.0018427]

9 **Legras JL**, Merdinoglu D, Cornuet JM, Karst F. Bread, beer and wine: Saccharomyces cerevisiae diversity reflects human history. *Mol Ecol* 2007; **16**: 2091-2102 [PMID: 17498234 DOI: 10.1111/j.1365-294X.2007.03266.x]

10 **Ochigava I**, Kalandarishvili L, Zhvania M. Immunological and central nervous system changes in mice suffering from Staphyloccocus aureus and treated with Saccharomyces cerevisiae var. vini living cells. *Folia Microbiol (Praha)* 2006; **51**: 659-663 [PMID: 17455807]

11 **Spiller R**, Pélerin F, Cayzeele Decherf A, Maudet C, Housez B, Cazaubiel M, Jüsten P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. *United European Gastroenterol J* 2016; **4**: 353-362 [PMID: 27403301 DOI: 10.1177/2050640615602571]

12 **Martins FS**, Elian SD, Vieira AT, Tiago FC, Martins AK, Silva FC, Souza EL, Sousa LP, Araújo HR, Pimenta PF, Bonjardim CA, Arantes RM, Teixeira MM, Nicoli JR. Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever. *Int J Med Microbiol* 2011; **301**: 359-364 [PMID: 21236729 DOI: 10.1016/j.ijmm.2010.11.002]

13 **West C**, Wu RY, Wong A, Stanisz AM, Yan R, Min KK, Pasyk M, McVey Neufeld KA, Karamat MI, Foster JA, Bienenstock J, Forsythe P, Kunze WA. Lactobacillus rhamnosus strain JB-1 reverses restraint stress-induced gut dysmotility. *Neurogastroenterol Motil* 2016 Jul 6; Epub ahead of print [PMID: 27381257 DOI: 10.1111/nmo.12903]

14 **Kunze WA**, Mao YK, Wang B, Huizinga JD, Ma X, Forsythe P, Bienenstock J. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. *J Cell Mol Med* 2009; **13**: 2261-2270 [PMID: 19210574 DOI: 10.1111/j.1582-4934.2009.00686.x]

15 **Ma X**, Mao YK, Wang B, Huizinga JD, Bienenstock J, Kunze W. Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. *Am J Physiol Gastrointest Liver Physiol* 2009; **296**: G868-G875 [PMID: 19179624 DOI: 10.1152/ajpgi.90511.2008]

16 **Mao YK**, Kasper DL, Wang B, Forsythe P, Bienenstock J, Kunze WA. Bacteroides fragilis polysaccharide A is necessary and sufficient for acute activation of intestinal sensory neurons. *Nat Commun* 2013; **4**: 1465 [PMID: 23403566 DOI: 10.1038/ncomms2478]

17 **Perez-Burgos A**, Wang B, Mao YK, Mistry B, McVey Neufeld KA, Bienenstock J, Kunze W. Psychoactive bacteria Lactobacillus rhamnosus (JB-1) elicits rapid frequency facilitation in vagal afferents. *Am J Physiol Gastrointest Liver Physiol* 2013; **304**: G211-G220 [PMID: 23139216 DOI: 10.1152/ajpgi.00128.2012]

18 **Wang B**, Mao YK, Diorio C, Pasyk M, Wu RY, Bienenstock J, Kunze WA. Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes. *FASEB J* 2010; **24**: 4078-4088 [PMID: 20519636 DOI: 10.1096/fj.09-153841]

19 **Wang B**, Mao YK, Diorio C, Wang L, Huizinga JD, Bienenstock J, Kunze W. Lactobacillus reuteri ingestion and IK(Ca) channel blockade have similar effects on rat colon motility and myenteric neurones. *Neurogastroenterol Motil* 2010; **22**: 98-107, e33 [PMID: 19788711 DOI: 10.1111/j.1365-2982.2009.01384.x]

20 **Wu RY**, Pasyk M, Wang B, Forsythe P, Bienenstock J, Mao YK, Sharma P, Stanisz AM, Kunze WA. Spatiotemporal maps reveal regional differences in the effects on gut motility for Lactobacillus reuteri and rhamnosus strains. *Neurogastroenterol Motil* 2013; **25**: e205-e214 [PMID: 23316914 DOI: 10.1111/nmo.12072]

21 **Kakunaga T**. The role of cell division in the malignant transformation of mouse cells treated with 3-methylcholanthrene. *Cancer Res* 1975; **35**: 1637-1642 [PMID: 1169110 DOI: 10.1046/j.1365-2982.2001.00282.x]

22 **Fida R**, Lyster DJ, Bywater RA, Taylor GS. Colonic migrating motor complexes (CMMCs) in the isolated mouse colon. *Neurogastroenterol Motil* 1997; **9**: 99-107 [PMID: 9198085 DOI: 10.1046/j.1365-2982.1997.d01-25.x]

23 **Smith TK**, Oliver GR, Hennig GW, O'Shea DM, Vanden Berghe P, Kang SH, Spencer NJ. A smooth muscle tone-dependent stretch-activated migrating motor pattern in isolated guinea-pig distal colon. *J Physiol* 2003; **551**: 955-969 [PMID: 12847208 DOI: 10.1113/jphysiol.2003.049163]

24 **Simpson JL**, Nadler HL. Maternal serum alpha-fetoprotein screening in 1987. *Obstet Gynecol* 1987; **69**: 134-135 [PMID: 2432449 DOI: 10.3389/fpsyg.2013.00863]

25 **Cumming G**, Finch S. Inference by eye: confidence intervals and how to read pictures of data. *Am Psychol* 2005; **60**: 170-180 [PMID: 15740449 DOI: 10.1037/0003-066X.60.2.170]

26 **Massi M**, Ioan P, Budriesi R, Chiarini A, Vitali B, Lammers KM, Gionchetti P, Campieri M, Lembo A, Brigidi P. Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. *World J Gastroenterol* 2006; **12**: 5987-5994 [PMID: 17009397]

27 **Burks TF**, Peterson JM, Williams, CL, Kramer TH. Restraint stress and intestinal transit in rats. In: Bueno L, Collins, S, Junien JL. Stress and digestive motility. London: John Libbey, 1989: 115–122

28 **Al-Nedawi K**, Mian MF, Hossain N, Karimi K, Mao YK, Forsythe P, Min KK, Stanisz AM, Kunze WA, Bienenstock J. Gut commensal microvesicles reproduce parent bacterial signals to host immune and enteric nervous systems. *FASEB J* 2015; **29**: 684-695 [PMID: 25392266 DOI: 10.1096/fj.14-259721]

**P-Reviewer:** Bi X, Garcia-Olmo D, Islek A, Soyturk M, Welch MG, Zhang ZJ **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Canada

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B,B, B

Grade C (Good): C,C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Effects of acute restraint stress on gut contractility, *ex vivo*.** A, C: Plot PCC velocity, frequency, and peak amplitude in the jejunum and colon respectively. The bar graphs show the mean difference between the control and treatment parameters. Stress decreased PCC velocity (*P <* 0.001) and frequency (*P <* 0.001) and increased peak amplitude in the jejunum (*P <* 0.001). Stress increased PCC velocity (*P <* 0.001) and frequency (*P =* 0.008), but had virtually no effect on peak amplitude in the colon (*P =* 0.902); B, D: Spatiotemporal diameter maps demonstrating contractility of the gut over time. The colour scale of the heat maps denote gut diameter starting from red for the smallest diameter (contraction) to green for the largest diameter (relaxation). The contractions run orally to anally across the vertical axis, and across time along the horizontal axis. Above the heat map is a plot of diameter vs. time or a single time-point along the vertical (oral-anal) axis, which is denoted by the horizontal line. The total vertical length of the map is 20 mm and time is 480 s for the jejunum and 560 s for the colon. The scale bar measures 1 min (60 s) horizontally and 2 mm vertically. All subsequent spatiotemporal (Dmaps) followed the same parameters.



**Figure 2 *Saccharomyces boulardii* increased motility across most parameters in the unstressed jejunum and decreased motility across parameters in the unstressed colon, *ex vivo*.** Mean differences in parameters are plotted (unpaired) and standard deviations of the mean are indicated. A: *Saccharomyces* *boulardii* (*S. boulardii*) increased PCC velocity and frequency, but had little to no effect on peak amplitude, in the unstressed jejunum; B: *S. boulardii* decreased PCC velocity, frequency, and peak amplitude in the unstressed colon.



**Figure 3 *Saccharomyces* *boulardii* reduced the effects of acute stress on the small and large intestine.** A, C: Mean paired differences, using 95%CIs across parameters for jejunum and colon [(Stressed + *S. boulardii*) – stressed]. *Saccharomyces* *boulardii* (*S. boulardii*) increased jejunal velocity and frequency after stress. *S. boulardii* decreased colonic velocity and frequency after stress. *S. boulardii* had little to no effect on peak amplitude in the stressed jejunum and colon. Mean differences straddled 0 for peak amplitude in both jejunum and colon; B, D: Dmaps comparing stressed jejunum and colon before and after addition of *S. boulardii*.



**Figure 4 *Saccharomyces cerevisiae* slightly increased parameters in both the unstressed small and large intestine (excluding colon peak amplitude).** A: 95%CIs for paired mean differences were near 0 for jejunal peak amplitude. Jejunal PCC velocity and frequency slightly increased; B: *Saccharomyces cerevisiae* (*S. cerevisiae*) had less potent effects in the colon, slightly increasing PCC velocity and frequency, but decreasing peak amplitude.



**Figure 5 *Saccharomyces cerevisiae* helped to reduce dysmotility in the stressed gut, with most visible effects on the jejunum.** A, C: *Saccharomyces cerevisiae* (*S. cerevisiae*) increased stressed jejunal PCC velocity and decreased velocity in the stressed colon. *S. cerevisiae* increased jejunal frequency and slightly decreased peak amplitude in both the colon and jejunum. 95%CIs straddled 0 for mean paired differences in colonic frequency; B, D: Dmaps representing the stressed gut before and after addition of *S. cerevisiae*. *S. cerevisiae* helped to restore jejunal motility after stress. *S. cerevisiae* had less potent effects on the stressed colon, but helped to ease some of the dysmotility.



**Figure 6 Addition of *Saccharomyces* *boulardii*** **supernatant to the stressed lumen recapitulated much of the effect of the boulardii yeast.** A: *Saccharomyces* *boulardii* (*S. boulardii*) Snt increased PCC velocity and frequency in the stressed jejunum. 95%CIs straddled 0 for mean paired differences in jejunal peak amplitude, showing no effect; B: *S. boulardii* Snt decreased PCC velocity and frequency in the stressed colon. *S. boulardii* Snt had little effect (very little increase) on stressed colonic peak amplitude and again the 95%CIs straddled 0 for mean paired differences.



**Figure 7 Addition of *Saccharomyces cerevisiae* supernatant to the stressed lumen had some therapeutic effect, but not across parameters.** A: *Saccharomyces cerevisiae* (*S. cerevisiae*) Snt had little effect on stressed jejunal PCC velocity. *S. cerevisiae* Snt increased stressed jejunal PCC frequency and decreased peak amplitude; B: *S. cerevisiae* Snt decreased both stressed colonic PCC velocity and peak amplitude. There was no effect on stressed colon PCC frequency.

|  |
| --- |
| **Table 1 Effects of stress on gut PCCs** |
| **Parameter** | **Tissue** | **Unstressed** | **Stressed** | ***P* value (*t* test)** |
| Velocity | Jejunum | 2.635 ± 0.316 (17) | 1.644 ± 0.238 (17) | < 0.001 |
| (mm/s) | Colon | 0.864 ± 0.183 (17) | 1.432 ± 0.329 (17) | < 0.001 |
| Frequency | Jejunum | 0.032 ± 0.008 (17) | 0.016 ± 0.005 (17) | < 0.001 |
| (Hz) | Colon | 0.005 ± 0.001 (17) | 0.007 ± 0.001 (17) | 0.008 |
| Peak amplitude | Jejunum | 0.437 ± 0.02 (17) | 0.79 ± 0.015 (17) | < 0.001 |
| (mm) | Colon | 0.64 ± 0.118 (17) | 0.645 ± 0.101 (17) | 0.902 |

|  |
| --- |
| **Table 2 Effects of *Saccharomyces boulardii* on PCCs in unstressed gut** |
| **Parameter** | **Tissue** | **Unstressed** | **+boulardii** | ***P* value (*t* test)** |
| Velocity | Jejunum | 2.556 ± 0.299 (32) | 3.229 ± 0.62 (32) | < 0.001 |
| (mm/s) | Colon | 0.865 ± 0.148 (27) | 0.633 ± 0.225 (27) | < 0.001 |
| Frequency | Jejunum | 0.030 ± 0.018 (33) | 0.035 ± 0.025 (33) | 0.030 |
| (Hz) | Colon | 0.009 ± 0.004 (27) | 0.007 ± 0.003 (27) | 0.005 |
| Peak amplitude | Jejunum | 0.587 ± 0.241 (33) | 0.623 ± 0.291 (33) | 0.29 |
| (mm) | Colon | 0.621 ± 0.19 (27) | 0.543 ± 0.179 (27) | 0.005 |

|  |
| --- |
| **Table 3 Effects of *Saccharomyces boulardii* on PCCs in stressed gut** |
| **Parameter** | **Tissue** | **Stressed** | **+boulardii** | ***P* value (*t* test)** |
| Velocity | Jejunum | 1.833 ± 0.688 (26) | 2.627 ± 0.664 (26) | < 0.001 |
| (mm/s) | Colon | 1.516 ± 0.263 (24) | 1.036 ± 0.21 (24) | < 0.001 |
| Frequency | Jejunum | 0.019 ± 0.013 (26) | 0.032 ± 0.024 (26) | 0.005 |
| (Hz) | Colon | 0.010 ± 0.003 (24) | 0.007 ± 0.003 (24) | 0.001 |
| Peak amplitude | Jejunum | 0.692 ± 0.215 (26) | 0.698 ± 0.212 (26) | 0.705 |
| (mm) | Colon | 0.719 ± 0.249 (24) | 0.657 ± 0.152 (24) | 0.259 |

|  |
| --- |
| **Table 4 Effects of *Saccharomyces cerevisiae* on PCCs in unstressed gut** |
| **Parameter** | **Tissue** | **Unstressed** | **+cerevisiae** | ***P* value (*t* test)** |
| Velocity | Jejunum | 2.779 ± 0.499 (43) | 3.017 ± 0.457 (43) | 0.017 |
| (mm/s) | Colon | 0.788 ± 0.212 (23) | 0.858 ± 0.257 (23) | 0.161 |
| Frequency | Jejunum | 0.027 ± 0.012 (43) | 0.031 ± 0.008 (43) | 0.003 |
| (Hz) | Colon | 0.0051 ± 0.001 (23) | 0.0054 ± 0.001 (23) | 0.462 |
| Peak amplitude | Jejunum | 0.409 ± 0.111 (43) | 0.438 ± 0.098 (43) | 0.242 |
| (mm) | Colon | 0.559 ± 0.176 (23) | 0.508 ± 0.15 (23) | 0.164 |

|  |
| --- |
| **Table 5 Effects of *Saccharomyces cerevisiae* on PCCs in stressed gut** |
| **Parameter** | **Tissue** | **Stressed** | **+cerevisiae** | ***P* value (*t* test)** |
| Velocity | Jejunum | 1.763 ± 0.397 (23) | 2.017 ± 0.48 (23) | 0.0031 |
| (mm/s) | Colon | 1.647 ± 0.187 (23) | 1.038 ± 0.222 (23) | <0.001 |
| Frequency | Jejunum | 0.016 ± 0.009 (23) | 0.027 ± 0.007 (23) | <0.001 |
| (Hz) | Colon | 0.008 ± 0.002 (23) | 0.008 ± 0.003 (23) | 0.994 |
| Peak amplitude | Jejunum | 0.761 ± 0.316 (23) | 0.559 ± 0.148 (23) | 0.013 |
| (mm) | Colon | 0.64 ± 0.101 (23) | 0.597 ± 0.103 (23) | 0.190 |

|  |
| --- |
| **Table 6 Effects of *Saccharomyces boulardii* supernatant on PCCs in stressed gut** |
| **Parameter** | **Tissue** | **Stressed** | **+boulardii Snt** | ***P* value (*t* test)** |
| Velocity | Jejunum | 1.97 ± 0.39 (6) | 2.585 ± 0.468 (6) | < 0.001 |
| (mm/s) | Colon | 1.588 ± 0.194 (6) | 1.11 ± 0.383 (6) | 0.038 |
| Frequency | Jejunum | 0.020 ± 0.014 (6) | 0.044 ± 0.027 (6) | 0.067 |
| (Hz) | Colon | 0.010 ± 0.001 (6) | 0.007 ± 0.003 (6) | 0.024 |
| Peak amplitude | Jejunum | 0.75 ± 0.285 (6) | 0.737 ± 0.187 (6) | 0.93 |
| (mm) | Colon | 0.65 ± 0.188 (6) | 0.701 ± 0.09 (6) | 0.59 |

|  |
| --- |
| **Table 7 Effects of *Saccharomyces cerevisiae* supernatant on PCCs in stressed gut** |
|  |  | **Stressed** | **+cerevisiae Snt** | ***P* value (*t* test)** |
| Velocity | Jejunum | 0.713 ± 0.109 (6) | 0.466 ± 0.122 (6) | 0.97 |
| (mm/s) | Colon | 1.639 ± 0.18 (6) | 1.018 ± 0.245 (6) | 0.002 |
| Frequency | Jejunum | 0.018 ± 0.004 (6) | 0.029 ± 0.004 (6) | 0.003 |
| (Hz) | Colon | 0.0076 ± 0.001 (6) | 0.0074 ± 0.001 (6) | 0.83 |
| Peak amplitude | Jejunum | 0.713 ± 0.109 (6) | 0.466 ± 0.122 (6) | 0.0016 |
| (mm) | Colon | 0.741 ± 0.177 (6) | 0.510 ± 0.202 (6) | 0.10 |